Katleen De Preter

28.6k citations

117 papers · 20.6k indexed · 1 hit paper · h-index 36

Molecular Biology top 0.2%
Cancer Research top 0.2%
Genetics top 0.5%
Plant Science top 0.5%
Immunology top 1%

Co-authors: Jo Vandesompele Nadine Van Roy Anne De Paepe Frank Speleman Filip Pattyn Bruce Poppe Pieter Mestdagh Francisco Avila Cobos
Topics: Neuroblastoma Research and Treatments (71 papers)Cancer, Hypoxia, and Metabolism (25 papers)Lung Cancer Research Studies (13 papers)
Cited by: Cancer Research Molecular Biology Neurology
Journals: Nucleic Acids Research Nature Communications Nature Genetics
Partner nations: Belgium Germany United States

In The Last Decade

Katleen De Preter

116 papers receiving 20.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

2002 16.7k citations Jo Vandesompele, Katleen De Preter et al. profile →

Peers

Countries citing papers authored by Katleen De Preter

Since Specialization

Citations

This map shows the geographic impact of Katleen De Preter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katleen De Preter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katleen De Preter more than expected).

Fields of papers citing papers by Katleen De Preter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katleen De Preter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katleen De Preter. The network helps show where Katleen De Preter may publish in the future.

Co-authorship network of co-authors of Katleen De Preter

This figure shows the co-authorship network connecting the top 25 collaborators of Katleen De Preter. A scholar is included among the top collaborators of Katleen De Preter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katleen De Preter. Katleen De Preter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma 2023 ·iScience ·(unknown),Yujie Fan,(unknown),Celine Everaert,Wouter Van Loocke,(unknown),(unknown),(unknown),(unknown),Vanessa Vermeirssen,Katleen De Preter,Ting Zhou,Alex Kentsis,Lorenz Studer,Frank Speleman,Stephen S. Roberts	2
2	From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma 2021 ·Journal of Personalized Medicine ·Bieke Decaesteker,Kaat Durinck,Nadine Van Roy,Bram De Wilde,Christophe Van Neste,(unknown),Stephen S. Roberts,Katleen De Preter,Vanessa Vermeirssen,Frank Speleman	2
3	DREAM target reactivation by core transcriptional regulators supports neuroblastoma growth 2019 ·Molecular & Cellular Oncology ·Bieke Decaesteker,Katleen De Preter,Frank Speleman	2
4	Benchmarking the impact of data transformation, pre-processing and choice of method in the computational deconvolution of transcriptomics data 2019 ·Francisco Avila Cobos,José Alquicira-Hernández,Jo Vandesompele,Joseph E. Powell,Pieter Mestdagh,Katleen De Preter	1
5	Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN 2018 ·Cancer Research ·(unknown),Daniel R. Carter,Bing Liu,Chelsea Mayoh,Anneleen Beckers,(unknown),Zsuzsanna Nagy,Sara De Brouwer,Bieke Decaesteker,Tzong‐Tyng Hung,Murray D. Norris,Michelle Haber,Tao Liu,Katleen De Preter,Frank Speleman,Belamy B. Cheung,Glenn M. Marshall	45
6	LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis 2018 ·Clinical Cancer Research ·(unknown),Matthias Fischer,Thomas F.E. Barth,Wolfgang Mueller‐Klieser,Barbara Hero,Judith Gecht,Daniel R. Carter,Katleen De Preter,Benjamin Mayer,(unknown),Frank Speleman,Glenn M. Marshall,Klaus‐Michael Debatin,Christian Beltinger	54
7	In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors 2018 ·Scientific Reports ·Suzanne Vanhauwaert,Bieke Decaesteker,Sara De Brouwer,Carina Leonelli,Kaat Durinck,Pieter Mestdagh,Jo Vandesompele,Karen Sermon,Geertrui Denecker,Christophe Van Neste,Frank Speleman,Katleen De Preter	7
8	IncGraph: Incremental graphlet counting for topology optimisation 2018 ·PLoS ONE ·Robrecht Cannoodt,Joeri Ruyssinck,Jan Ramon,Katleen De Preter,Yvan Saeys	2
9	Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients 2017 ·Clinical Cancer Research ·Nadine Van Roy,Malaïka Van Der Linden,Björn Menten,Annelies Dheedene,(unknown),Jo Van Dorpe,Geneviève Laureys,Marleen Renard,Tom Sante,Tim Lammens,Bram De Wilde,Frank Speleman,Katleen De Preter	81
10	The MYCN/miR-26a-5p/LIN28B regulatory axis controls MYCN-driven LIN28B upregulation in neuroblastoma 2014 ·Ghent University Academic Bibliography (Ghent University) ·Anneleen Beckers,Andrew D. Ludwig,Gert Van Peer,Daniel R. Carter,Belamy B. Cheung,Sara De Brouwer,Jo Vandesompele,Katleen De Preter,Jason M. Shohet,Frank Speleman	1
11	Genetisch geïnspireerde toekomstperspectieven voor de therapie van het neuroblastoom 2014 ·Ghent University Academic Bibliography (Ghent University) ·Bram De Wilde,Tom Van Maerken,Katleen De Preter,Nadine Van Roy,Geneviève Laureys,Jo Vandesompele,Frank Speleman	1
12	Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma 2013 ·Cancer Research ·Eveline Barbieri,Katleen De Preter,Mario Capasso,Zaowen Chen,(unknown),Gian Paolo Tonini,Steve Lefever,John Hicks,Rogier Versteeg,Andrea Pession,Frank Speleman,Eugene S. Kim,Jason M. Shohet	44
13	MiR-137 is epigenetically silenced in MYCN amplified neuroblastomas and targets the polycomb repressive complex 2 (PRC2) component EZH2 2012 ·Ghent University Academic Bibliography (Ghent University) ·Anneleen Beckers,Maté Ongenaert,Anneleen Decock,Candy Kumps,Filip Pattyn,Pieter Mestdagh,Johannes H. Schulte,Frank Speleman,Katleen De Preter	1
14	High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma 2011 ·Clinical Cancer Research ·Johannes H. Schulte,Hagen S. Bachmann,(unknown),Katleen De Preter,André Oberthür,Sandra Ackermann,Yvonne Kahlert,Kristian W. Pajtler,Jessica Theißen,Frank Westermann,Jo Vandesompele,Frank Speleman,Frank Berthold,Angelika Eggert,Benedikt Brors,Barbara Hero,Alexander Schramm,Matthias Fischer	72
15	The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors 2010 ·Molecular Cancer Therapeutics ·Deborah Castelletti,Giulio Fiaschetti,Valeria Di Dato,Urs Ziegler,Candy Kumps,Katleen De Preter,Massimo Zollo,Frank Speleman,Tarek Shalaby,Daniela De Martino,Thorsten Berg,Angelika Eggert,Alexandre Arcaro,Michael A. Grotzer	11
16	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature 2010 ·Clinical Cancer Research ·Katleen De Preter,Joëlle Vermeulen,Benedikt Brors,Olivier Delattre,Angelika Eggert,Matthias Fischer,Isabelle Janoueix‐Lerosey,Cinzia Lavarino,John M. Maris,Jaume Mora,Akira Nakagawara,André Oberthuer,Miki Ohira,Gudrun Schleiermacher,Alexander Schramm,Johannes H. Schulte,Qun Wang,Frank Westermann,Frank Speleman,Jo Vandesompele	65
17	Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q− Neuroblastoma 2010 ·Clinical Cancer Research ·Patrick G. Buckley,Leah Alcock,Kenneth Bryan,Isabella Bray,Johannes H. Schulte,Alexander Schramm,Angelika Eggert,Pieter Mestdagh,Katleen De Preter,Jo Vandesompele,Frank Speleman,Raymond L. Stallings	54
18	Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds 2009 ·Clinical Cancer Research ·Katleen De Preter,Sara De Brouwer,Tom Van Maerken,Filip Pattyn,Alexander Schramm,Angelika Eggert,Jo Vandesompele,Frank Speleman	37
19	Integrative genomics in neuroblastoma research 2007 ·Ghent University Academic Bibliography (Ghent University) ·Frank Speleman,Katleen De Preter,Evi Michels,Jasmien Hoebeeck,Filip Pattyn,Joëlle Vermeulen,Nadine Van Roy,Anne De Paepe,Geneviève Laureys,Jo Vandesompele	1
20	A detailed inventory of DNA copy number alterations in four commonly used Hodgkin lymphoma cell lines 2007 ·Ghent University Academic Bibliography (Ghent University) ·Tom Feys,Bruce Poppe,Katleen De Preter,Nadine Van Roy,Bruno Verhasselt,Pascale De Paepe,Anne De Paepe,Frank Speleman	1

About Katleen De Preter

Katleen De Preter is a scholar working on Neurology, Cancer Research and Molecular Biology, having authored 117 papers that have together received 20.6k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (71 papers), Cancer, Hypoxia, and Metabolism (25 papers) and Lung Cancer Research Studies (13 papers). The work is most often cited by research in Cancer Research (3.4k citations), Molecular Biology (11.6k citations) and Neurology (1.7k citations). Katleen De Preter has collaborated with scholars based in Belgium, Germany and United States. Frequent co-authors include Jo Vandesompele, Nadine Van Roy, Anne De Paepe, Frank Speleman, Filip Pattyn, Bruce Poppe, Frank Speleman, Pieter Mestdagh, Francisco Avila Cobos and Geneviève Laureys. Their work appears in journals such as Nucleic Acids Research, Nature Communications and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact